Back

The influence of concomitant antiplatelet therapy in venous thromboembolism patients treated with anticoagulants in the DOAC era: insight from the COMMAND VTE Registry-2

1 September 2024 (17:36 - 17:48)
Organised by: Logo
Congress Presentation Part of: Cardiovascular treatment: protecting the brain and the limbs Venous Disease ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor Kazuhisa Kaneda

Kyoto University Graduate School of Medicine, Kyoto (Japan)

4 More presentations in this session

Presentation thumbnail
Remnant cholesterol, not LDL cholesterol, explains peripheral artery disease risk conferred by apolipoprotein B: a cohort study
Doctor B. Nilsson Wadstrom (Copenhagen, DK)
Abstract Slides Video
Presentation thumbnail
The evolution of carotid atherosclerotic plaque composition: a prospective study
Mr L. Zuo (Rotterdam, NL)
Abstract Slides Video
Presentation thumbnail
Extracranial systemic embolic events in patients with atrial fibrillation: an individual patient-level meta-analysis of 71 683 patients randomized to NOAC vs warfarin from the COMBINE-AF study
Doctor S. Al Said (Boston, US)
Abstract Slides Video
Presentation thumbnail
Drug-eluting devices versus angioplasty in infrapopliteal artery disease:an updated systematic review and meta-analysis
Mr E. Katsuyama (Santo Andre, BR)
Abstract Slides Video

Access the full session

Session thumbnail
Cardiovascular treatment: protecting the brain and the limbs
Video

The Event

Event poster

ESC Congress 2024

1 September 2024 17:36 CET
You may be interested in
thumbnail
Congress Presentation
The initial high-dose versus maintenance-dose anticoagulation therapy with direct oral anticoagulants for cancer-associated venous thromboembolism: from the COMMAND VTE Registry-2
thumbnail
Congress Presentation
Clinical features and long-term outcomes of venous thromboembolism in the warfarin era versus in the direct oral anticoagulant era
thumbnail
Congress Presentation
Clinical features and long-term outcomes of cancer-associated venous thromboembolism: transition from the warfarin era to the direct oral anticoagulant era

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources